Biofrontera (BFRI) Stock Forecast, Price & News

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biofrontera in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" BFRI shares.
View BFRI analyst ratings or view top-rated stocks.

1 Wall Street research analysts have issued twelve-month price objectives for Biofrontera's shares. Their BFRI share price forecasts range from $18.00 to $18.00. On average, they expect the company's share price to reach $18.00 in the next year. This suggests a possible upside of 112.0% from the stock's current price.
View analysts price targets for BFRI or view top-rated stocks among Wall Street analysts.

Biofrontera's stock was trading at $18.3320 at the beginning of the year. Since then, BFRI stock has decreased by 53.7% and is now trading at $8.49.
View the best growth stocks for 2023 here.

Biofrontera saw a increase in short interest in September. As of September 15th, there was short interest totaling 21,000 shares, an increase of 9.4% from the August 31st total of 19,200 shares. Based on an average daily volume of 16,600 shares, the short-interest ratio is presently 1.3 days. Approximately 2.7% of the company's stock are sold short.
View Biofrontera's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our BFRI earnings forecast.

Biofrontera Inc. (NASDAQ:BFRI) released its quarterly earnings results on Friday, August, 11th. The company reported ($6.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($5.14) by $1.00. The business earned $5.85 million during the quarter, compared to analyst estimates of $5.86 million. Biofrontera had a negative trailing twelve-month return on equity of 126.98% and a negative net margin of 78.03%.

Shares of Biofrontera reverse split on the morning of Wednesday, July 5th 2023. The 1-20 reverse split was announced on Wednesday, July 5th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, July 5th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Biofrontera updated its FY 2023 earnings guidance on Sunday, September, 3rd. The company provided EPS guidance of for the period. The company issued revenue guidance of $35.84M-.

(BFRI) raised $19 million in an initial public offering on Friday, October 29th 2021. The company issued 3,100,000 shares at a price of $5.00-$7.00 per share. Roth Capital Partners and The Benchmark Company served as the underwriters for the IPO.

Biofrontera trades on the NASDAQ under the ticker symbol "BFRI."

Shares of BFRI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BFRI stock can currently be purchased for approximately $8.49.

Biofrontera (NASDAQ:BFRI) has a market capitalization of $11.63 million and generates $28.67 million in revenue each year. The company earns $-640,000.00 in net income (profit) each year or ($17.83) on an earnings per share basis.

The official website for the company is www.biofrontera-us.com. The company can be reached via phone at 781-245-1325 or via email at us-ir@biofrontera.com.